

Haematologica  
HAEMATOL/2019/218883  
Version 2

Rituximab in the treatment of immune thrombocytopenia: what role for  
this agent in 2019?

Elisa Lucchini, Francesco Zaja, and James Bussel

Disclosures: EL none FZ received honoraria from Roche for lectures to medical meetings or advisory boards JB Consultant: Amgen, Novartis, Dova, Sunshine Bio, Rigel, UCB, Argenx, Momenta, Rally Bio, Tranquil, Regeneron. Speaker: Novartis.

Contributions: All the authors equally contributed to this paper